Evaluating lurasidone as a treatment option for bipolar disorder.

Evaluating lurasidone as a treatment option for bipolar disorder. Expert Opin Pharmacother. 2020 Jan 19;:1-8 Authors: Ali Z, Tegin C, El-Mallakh RS Abstract Introduction: Lurasidone has been approved in the United States as a monotherapy and adjunct for acute bipolar I depression, as well as an antipsychotic for patients with schizophrenia.Areas covered: Herein, the authors review the pharmacodynamics and pharmacokinetics of lurasidone as well and the major randomized clinical trials. The authors also provide their expert opinion.Expert opinion: Lurasidone has not been studied in patients with mania or bipolar psychosis. It has been studied, both as a monotherapy and adjunctive treatment to lithium or valproate, in acute depression and in prevention of recurrence of any mood episode in patients with bipolar disorder initially treated for bipolar depression or mania. It is approved in the United States for acute bipolar I depression. It has clinically meaningful treatment effect sizes for improvement in depression compared to placebo (0.51 monotherapy, 0.34 adjunct). The number needed to treat (NNT) for response with monotherapy was 5 (for both lower and higher dose groups), and for remission was 6 and 7 (for lower dose and higher dose groups, respectively); the NNT for adjunctive therapy was 7. It has not demonstrated efficacy in relapse prevention when added to a mood stabilizer but is safe in combination with other medications. PMID: 31957501 [PubMe...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Related Links:

Authors: Petrasch-Parwez E, Schöbel A, Benali A, Moinfar Z, Förster E, Brüne M, Juckel G Abstract There is increasing evidence from genetic, biochemical, pharmacological, neuroimaging and post-mortem studies that immunological dysregulation plays a crucial role in the pathogenesis of psychoses. The involvement of microglia in schizophrenia and bipolar disorder (BD) has remained controversial, however, since results from various post-mortem studies are still inconclusive. Here, we analyzed the estimated density of microglia of age-matched individuals with schizophrenia (n = 17), BD (n&th...
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research
Often we don’t really consider gender dynamics in treatment or medication. A lot of medications are only tested on men because of the risk of pregnancy, etc. This means there are whole drugs that have made it to market that may not have ever been tested with women. Schizophrenia affects women in many different ways than men. In this episode schizophrenic Rachel Star Withers and cohost Gabe Howard discuss differences in age, symptoms, treatments, lifestyle, parenthood in the genders as they experience schizophrenia. Dr. Hayden Finch joins to explain the medical side.  Highlights in “Schizophrenia in Women...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Inside Schizophrenia Mental Health and Wellness Women's Issues Gender Differences Mental Disorder Mental Illness Psychiatry Psychology Psychotherapy Women's Health women's mental health Source Type: blogs
This study uses state administrative data to examine service continuation among those aging out of child system services in Texas (N = 3135). Most (63.5%) did not enroll in adult services following their 18th birthday. Binary logistic regression analyses found that significant predictors of child-to-adult service continuation included (1) a serious primary mental health diagnosis (i.e., schizophrenia, bipolar disorder, major depressive disorder), (2) risks to self and others, and (3) number of prior-year mental health services received. These findings suggest that historical mental health policies and practices...
Source: The Journal of Behavioral Health Services and Research - Category: Psychiatry & Psychology Source Type: research
Over this past weekend, I participated in my first outreach event for Mental Health America at the NBC4 Telemundo 44 Health and Fitness Expo in Washington, D.C.  Dr. Martin Luther King said that people “fear each other because they do not know each other.  They do not know each other because they do not communicate with each other.”  Here is what I learned at the event: it is easy to communicate with people about mental health because the topic is accessible across culture, race and age. In addition, talking about mental health is especially important to those with mental illness. We had a s...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Communication Conferences General Mental Health America Mental Health and Wellness Policy and Advocacy Publishers connection Mental Health Advocacy Mental Health Policy Source Type: blogs
  Do you struggle with anger? Did you know that some of our most hot-headed moments are actually rooted in anxiety? In today’s podcast, Jackie openly shares her own fuse-blowing moment when her husband’s keys were (gasp!) missing from the hook, and now she must face being late for therapy and perhaps even lie dying on the side of the road. How did she handle this catastrophic situation her mind so graciously forewarned her about? Does this sound familiar? Join us as we discuss anxiety-driven anger and explore ways to minimize and possibly even prevent it. (Transcript Available Below) SUBSCRIBE &REVIEW...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Anger Anxiety and Panic Disorders General Not Crazy Podcast Psychology Source Type: blogs
Authors: Kolomeets NS, Uranova NA Abstract There is increasing evidence to support the notion that oligodendrocyte and myelin abnormalities may contribute to the functional dysconnectivity found in the major psychiatric disorders. The putamen, which is an important hub in the cortico-striato-thalamo-cortical loop, has been implicated in a broad spectrum of psychiatric illnesses and is a central target of their treatments. Previously we reported a reduction in the numerical density of oligodendrocytes and oligodendrocyte clusters in the prefrontal and parietal cortex in schizophrenia. Oligodendrocyte clusters contai...
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research
CONCLUSIONS: Our study demonstrates that psychiatric PRSs provide modest independent discrimination between BD and MDD cases, suggesting that PRSs could ultimately have utility in subjects at the extremes of the distribution and/or subjects for whom clinical symptoms are poorly measured or yet to manifest. PMID: 32063240 [PubMed - as supplied by publisher]
Source: Psychological Medicine - Category: Psychiatry Authors: Tags: Psychol Med Source Type: research
Conclusions: Certain modifiable risk factors play an inescapable role in increasing the level of burden among caregivers of older patients with serious mental illnesses.Clinical Implications: Improving the quality of life and psychological well-being of family caregivers should be considered an integral part of treatment for serious mental illness in older adult patients. PMID: 32058858 [PubMed - as supplied by publisher]
Source: Clinical Gerontologist - Category: Geriatrics Tags: Clin Gerontol Source Type: research
AbstractThere is increasing evidence from genetic, biochemical, pharmacological, neuroimaging and post-mortem studies that immunological dysregulation plays a crucial role in the pathogenesis of psychoses. The involvement of microglia in schizophrenia and bipolar disorder (BD) has remained controversial, however, since results from various post-mortem studies are still inconclusive. Here, we analyzed the estimated density of microglia of age-matched individuals with schizophrenia (n = 17), BD (n = 13), and non-psychiatric control subjects (n = 17) in the anterior midcingulate corte...
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Neuroscience Source Type: research
This article summarizes the milestones in the development of lumateperone leading to this first approval for the treatment of schizophrenia.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Bipolar | Clinical Trials | Depression | Drugs & Pharmacology | Lithium | Mania | Schizophrenia | USA Health